Schizophrenic Disorders
21
1
1
15
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
9.5%
2 terminated out of 21 trials
88.2%
+1.7% vs benchmark
33%
7 trials in Phase 3/4
33%
5 of 15 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 15 completed trials
Clinical Trials (21)
Interest of EMDR Schizophrenic Disorders
Neuropsychological Assessment of Remediation for Cognitive Impairments in Schizophrenia
A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With Schizophrenia
Have a Good Grasp of the Worldthe World
Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.
Upside Down, Give me the Handle
Effectiveness of a Physical Activity and Diet Program in Patients With Psychotic Disorder (CapiCor)
Sodium Butyrate For Improving Cognitive Function In Schizophrenia
Interest of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Auditory Hallucinations
Sarcosine Preventive Therapy for Individuals At High Risk for Schizophrenia
Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone
The Psychiatric Rehabilitation Approach to Weight Loss
Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder
D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic Schizophrenia
Clozapine/Paliperidone Versus Clozapine/Placebo in Resistant Schizophrenia
Study in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose
Sarcosine or D-Serine Add-on Treatment for Chronic Schizophrenia
Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia
Assessment of a Weight Management Program for Weight Gain in Patients With Schizophrenia
Sarcosine (N-Methylglycine) Monotherapy for Schizophrenia